Login / Signup
Letter: using a placebo as a comparator to rifaximin for the primary prophylaxis of spontaneous bacterial peritonitis-is there really an ethical concern?
Thierry Thevenot
null null
Published in:
Alimentary pharmacology & therapeutics (2019)
Keyphrases
</>
double blind
irritable bowel syndrome
decision making
phase iii
clinical trial